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Defined key terms:  
Specific IgE: Subset of IgE antibodies involved in triggering an allergic reaction to a specific 
protein 
Tus-Ter-lock: A highly stable protein-DNA complex involved in DNA replication 
termination. 
Immuno-PCR: Detection of an antigen or antibody by using a specialised protein-DNA 
conjugate containing a template that can be amplified and visualised by PCR. 
Tropomyosin: An α-helical coiled-coil actin-binding protein involved in muscle contraction. 
This protein is the major allergenic component causing allergy to shellfish. 
ImmunoCAP: A commercially available specific IgE quantification system for the diagnosis 
of allergic sensitisation.  
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Abstract 
Background: The increasing prevalence of food allergies requires development of specific 
and sensitive tests capable of identifying the allergen responsible for the disease. The 
development of serologic tests that can detect specific IgE antibodies to allergenic proteins 
would therefore be highly received.  
Results: Here we present two new quantitative immuno-PCR assays for the sensitive 
detection of antibodies specific to the shrimp allergen tropomyosin. Both assays are based on 
the self-assembling Tus-Ter-lock protein-DNA conjugation system. Significantly elevated 
levels of tropomyosin-specific IgE were detected in sera from patients allergic to shrimp. 
Conclusions: This is the first time an allergenic protein has been fused with Tus to enable 
specific IgE antibody detection in human sera by quantitative immuno-PCR. 
Introduction 
Food allergies are an increasing problem world-wide, with 3-8% of people suffering some 
form of food allergy [1-3]. The correct diagnosis of food allergies is often cumbersome, with 
no single test being definitive.  The diagnostic approach usually starts with a medical and 
dietary history followed by skin prick tests and/or serum IgE detection tests. The occurrence 
of false positive and false negative results with these tests means that oral food challenges 
often need to be completed to fully confirm clinical reactivity to a food allergen. As there are 
risks associated with oral food challenges and skin prick tests, accompanied with the lack of 
standardised procedures and reagents, the use of in vitro serum tests (immunoassays) for 
diagnosis is often preferred. Food-specific IgE assays are performed as total IgE is not well 
correlated with the presence of clinical allergy [4]. 
The first commercial test for the detection of specific IgE antibodies (sIgE) was the 
radioallergosorbent test, put in use in 1974 [5]. This used a radiolabelled anti-IgE to quantify 
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the amount of IgE specific to an allergen. This was replaced by the improved fluorescence 
enzyme-labelled assay, ImmunoCAP (Phadia, Uppsala, Sweden) [6, 7] in 1989. The 
ImmunoCAP system is the most widely available commercial allergy detection test and has 
become the Gold standard in in vitro IgE quantification. This solid phase sandwich 
immunoassay has an allergen mix covalently coupled to a matrix, in which sIgE from serum 
is captured and then detected using enzyme-labelled anti-IgE antibody. Another commercial 
system that uses a chemiluminescent detection system has been developed to detect multiple 
allergens at once (MAST-CLA: multiple allergosorbent test – chemiluminescent assay; [8, 9]. 
This assay revealed equivalent results to ImmunoCAP [10]. In the past several other IgE 
detection assays were developed but none have been able to improve on the sensitivity and 
specificity of ImmunoCAP [11-17]. The ImmunoCAP and the Immulite systems 
(chemiluminescent detection system, Siemens Healthcare) [18] have a limit of quantitation of 
0.1 kU/l, with the lower cut-off for allergy being 0.35 kU/l.  
With the difficulty of standardising food preparations purified and recombinant allergens are 
being used increasingly in diagnosis. This has opened the door for the field of component-
resolved diagnostics. As more allergenic proteins are characterised and pure and/or 
recombinant forms become available, a whole array of peptides (such as IgE-binding 
epitopes) can be screened for patient sensitivity. This is especially important as foods 
containing homologous proteins can cross-react putting an individual at further risk of allergy 
[19, 20]. Recently, microarray technology has been shown to be useful in the profiling of 
allergen sensitisation in allergic patients [21-24]. Phadia has released the ImmunoCAP ISAC 
(Immuno Solid-phase Allergen Chip) and it has already been put in use in some countries. 
In this study we use shellfish allergy and its major allergenic protein tropomyosin (TM) to 
display new methods in the detection of allergen-sIgE antibodies. Shellfish allergy is among 
the most common of adult food allergies with approximately 2% of people being affected 
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[25]. The identified allergens include TM [26, 27], arginine kinase [28], myosin light chain 
[29], and sarcoplasmic calcium-binding protein [30]. TM is an essential actin-binding protein 
involved in muscle contraction. Due to the highly conserved nature of tropomyosins there can 
be cross-reactivity against several invertebrate species of crustaceans, molluscs, insects and 
mites [31, 32]. New assays are therefore needed for the more sensitive detection of allergy to 
specific crustacean and related species.  
DNA-based detection methods are being increasingly used in diagnostic assay development 
but they are yet to be well established in the diagnosis of allergies. The detection of a protein 
by immuno-PCR has become a popular method in recent years [33-35]. It is performed in a 
similar manner to ELISA except an antibody-DNA conjugate is used in order to amplify the 
signal by PCR. Common methods for coupling the antibody and DNA include a bridge with 
biotinylated DNA and a streptavidin-protein A fusion [36], biotinylated antibody coupled 
with streptavidin and biotinylated DNA [37, 38] and direct conjugation by chemical 
crosslinking [39]. More recently the Tus-Ter-lock (TT-lock) has been incorporated into a new 
immuno-PCR system [40-43]. Tus is a monomeric DNA-binding protein involved in DNA 
replication termination in Escherichia coli that forms a very stable complex with Ter-lock 
DNA sequences (TT-lock; KD 1 nM, half life 1 h in 0.25 M potassium chloride) [44-50]. 
Another DNA-based detection method replaces the PCR step with rolling circle amplification 
[51] and has previously been demonstrated in the detection of sIgE [52]. This method 
generates a concatamer of circular DNA copies attached to an anti-IgE antibody that can be 
detected by fluorescent complimentary oligonucleotide probes. 
Here we report the development of two new quantitative immuno-PCR (qIPCR) assays 
building on the TT-lock qIPCR platform [40-42]. We have engineered two new detection 
devices for the sensitive detection of TM-specific antibodies: TM tagged with the 
haemagglutinin A epitope (TM-HA) and Tus-TM (Figure 1). Both assays use a Ter-lock 
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DNA extended with a single-stranded PCR template (TT-lock-T) for the detection of TM-
specific antibodies by qPCR. The performances of both assays were compared using a TM-
specific IgG (TM-sIgG) from rabbit. The Tus-TM TT-lock qIPCR was successfully applied 
for the sensitive detection of human TM-specific IgE (TM-sIgE) present in sera obtained 
from patients allergic to shrimp.  
 
Materials and Methods 
Plasmid Construction 
Cloning experiments were performed in E. coli DH12S. To create a Tus-tropomyosin (Tus-
TM) fusion, the Penaeus monodon (black tiger shrimp) tropomyosin gene (Pen m 1) was 
subcloned from pRSET-A-TM (Kamath et al., submitted) into p-Tus-HA [42]. This was done 
by digesting each plasmid with BamHI and EcoRI restriction enzymes thereby removing Pen 
m 1 from pRSET-A-TM and inserting it at the 3’-end of tus in p-Tus-HA. This step also 
removed the HA-tag. The resulting plasmid was named pEJ226 and allowed the production 
of Tus-TM with an N-terminal hexahistidine (His6) tag (Figure 1B).  
To create the TM-HA fusion protein Pen m 1 was amplified from pRSET-A-TM (primers 5’- 
tgacgataaggatcgatgggg and 5’-gaattcaagcttgtagccagacagttcgctg), digested with BamHI and 
HindIII and inserted into similarly digested pET-GFP-HA [41], thereby inserting Pen m 1 in 
place of gfp. The resulting plasmid was named pEJ227 and allowed the production of TM-
HA with a C-terminal hexahistidine tag (Figure 1A). The integrity of the inserted DNA was 
confirmed by DNA sequencing (Australian Genome Research Facility, Brisbane, Australia), 
using primers that bind to the phage T7 promoter and terminator regions in the vector. 
Protein Overproduction and Purification 
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E. coli BL21(DE3)RIPL was used for overexpression of Tus-TM and TM-HA. Cells from a 
fresh transformation were used to inoculate 50-100 mL Overnight Express Instant TB 
Medium (Merck, Germany), supplemented with 1% glycerol (v/v), and grown at 16°C for 3-4 
days. Cell pellets were resuspended in 7.5 ml/g cold lysis buffer (50 mM NaH2PO4/Na2HPO4 
(pH 7.8), 300 mM NaCl, 10 % glycerol (v/v), 2 mM β-mercaptoethanol, 10 mM imidazole) 
and homogeneized by two passages through a French pressure cell (12,000 psi). The lysates 
were centrifuged at 18,000 g, at 4°C for 45 min. Soluble lysate was passed through a 2 ml 
nickel resin column (profinity IMAC Ni-charged resin, Bio-Rad, 156-0135) and washed with 
10-15 column volumes of lysis buffer. Proteins were eluted with 3 column volumes of elution 
buffer (lysis buffer with 200 mM imidazole) and snap frozen for storage at -80°C. 
Tus-TM required further purification. Gel filtration was carried out using a superdex 200 
10/300 GL column (GE Healthcare) and a BioLogic DuoFlow system (Bio-Rad). Nickel 
affinity elution fractions were injected 300 µl at a time and elution proceeded at 0.25 ml/min 
with GF buffer (50 mM NaH2PO4/Na2HPO4 (pH 7.5), 300 mM NaCl, 10 % glycerol (v/v), 2 
mM β-mercaptoethanol). 
Purity of proteins was evaluated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
using 10% acrylamide gels, resolved at 200 V for ~45 min and concentrations determined by 
Bradford Assay. 
Electrophoretic Mobility Shift Assay (EMSA) 
Four volumes of Tus-TM (in GF buffer) or Tus-HA (in 50 mM NaH2PO4/Na2HPO4 (pH 7.8), 
10 % glycerol (v/v), 2 mM β-mercaptoethanol) were mixed with one volume TerC [46] DNA 
in phosphate buffer (PB: 50 mM NaH2PO4/Na2HPO4 pH 7.8) in a 20 µl reaction volume, and 
incubated for 15 min at room temperature. Mixtures contained 0.5 µM TerC and 2 µM Tus-
TM or Tus-HA. 10 µl of each reaction was run on a 2% agarose gel at 100 V for 60 min, then 
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stained in GelRed solution for 15-30 min and visualised using a Gel Doc XR system (Bio-
Rad). 
Antibodies and Patient Sera 
Antibodies used in the study were acquired as follows: goat anti-rabbit IgG conjugated to 
horse radish peroxidase (anti-rabbit-HRP) purchased from Promega (W4011); rabbit anti-
human IgE purchased from DAKO Corporation (A0094); rat anti-HA IgG (anti-HA) 
purchased from Roche (11867423001); mouse anti-His6 (2) purchased from Roche 
(04905318001); anti-rat IgG conjugated to HRP (anti-rat-HRP) purchased from Abcam 
(ab6734); anti-TM (rabbit anti-TM, referred to as TM-sIgG) was made in-house with the help 
of IMVS, SA, Australia (130 µg/ml; Kamath et al., submitted). 
Control serum samples were purchased from Sigma (human AB, male, H4522) and 
Invitrogen (human AB, 34005). Patient sera were kindly provided by Robyn E. O’Hehir and 
Jennifer Rolland, The Alfred Hospital, Melbourne, VIC, Australia. Subjects with a clinical 
history of reactivity to shellfish and one non-atopic subject were recruited by The Alfred 
Hospital, Allergy Clinic. Informed consent was obtained from all subjects and all 
experiments performed in compliance with institutional guidelines. Ethics approval for this 
study was granted by James Cook University Ethics committee (Project number H4313) in 
collaboration with The Alfred Hospital (Project number 192/07) and Monash University 
(MUHREC CF08/0225) Ethics Committees. 
Western blot 
TM-HA and Tus-TM were resolved by SDS-PAGE on 12% acrylamide gels and transferred 
to nitrocellulose membrane using a Trans-Blot Turbo blotting system (Bio-Rad). Membranes 
were blocked overnight at 4°C with 5% skim milk in phosphate buffered saline (PBS). All 
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antibodies were diluted in PBS-T (PBS, 0.05% Tween 20) containing 1% skim milk. Primary 
antibodies TM-sIgG and anti-HA were diluted 1:2000 and 1:1000, respectively. Secondary 
antibodies anti-rabbit-HRP and anti-rat-HRP were diluted 1:5000 and 1:2000, respectively. 
Membranes were incubated for 1 h with primary antibody then washed three times for 5 min 
with PBS-T. Next membranes were incubated for 1 h with secondary antibody followed by 
three washes of 5 min with PBS-T. Bands were developed with SigmaFAST 3,3’-
Diaminobenzidine (Sigma, D4418). 
IgE Immunoblot 
TM-HA (10 μg) was loaded on to a 12% acrylamide gel with a single well comb and resolved 
by SDS-PAGE. The proteins were transferred to an activated PVDF membrane (Bio-Rad). 
All incubation steps were done at room temperature for 1 h with shaking, unless otherwise 
stated. The membrane was blocked with 5% skim milk powder in PBS-T. Patient sera were 
diluted 1:10 in 1% skim milk-PBS-T and added to the membrane using a slot blot apparatus 
(Idea Scientific). Binding was performed overnight under gentle shaking at 4°C. After 
washing three times with PBS-T, the membrane was incubated with rabbit anti-human IgE 
diluted 1:8000 in 1% skim milk-PBS-T, washed three times, then incubated with anti-rabbit-
HRP diluted 1:10,000 in 1% skim milk-PBS-T. After washing three times with PBS-T, the 
membrane was developed using enhanced chemiluminescence (ECL) [53] with Pierce ECL 
Western Blotting Substrate (32106). 
Preparation of anti-HA:Tus-HA:TT-lock-T detection device 
The TT-lock-T DNA probe was prepared as previously described [41].  Tus-HA was diluted 
to 0.5 µM in block buffer and 1.5 µl was mixed with 0.75 µl of TT-lock-T (1 µM). The 
mixture was incubated at room temperature for 10 min. The anti-HA (1.5 µl at 100 µg/ml) 
was added to the mixture and incubated for a further 5 min to obtain the anti-HA:Tus-
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HA:TT-lock-T detection device. The complex was then diluted in block buffer to a final 
concentration of 0.5 nM. 
TM-HA TT-lock qIPCR assay 
All washes were done using a Biosan microplate washer (Inteliwasher 3D-IW8, Fisher 
Biotec,  Australia) with 200 µl wash buffer (BW: 20 mM Tris-HCl (pH 8), 150 mM NaCl, 
0.005% Tween 20). All incubations were done at room temperature unless otherwise stated. 
Wells (MaxiSorp 96 well round-bottom plate, Nunc) were coated overnight at 4°C with 50 µl 
of capture antibody diluted to 10 µg/ml in PB. Wells were washed once then blocked with 
100 µl block buffer (BW + 1% BSA (w/v)) for 60-90 min, and washed again. 50 µl TM-sIgG 
dilutions (10-fold serial dilution 10 nM - 10 fM in block buffer) were added to the wells and 
incubated for 90 min. Wells were then washed three times and 5 nM TM-HA (diluted in 
block buffer) added for 60 min. After three more washes the anti-HA:Tus-HA:TT-lock-T 
detection device was added and incubated for 5 min. Following five washes, 50 µl of 39/40 
primer mix (39: 5'-caccgctgagcaataactagcat, 40: 5'-accgctgttgagatccagttc, diluted to 0.5 µM in 
water) were added and incubated for 60 min to allow the complex to dissociate.  
Aliquots (10 µl) were taken from wells and mixed with 10 µl of real-time PCR mix 
(SensiMix SYBR and fluorescein kit, Bioline, QT615-05) to perform qPCR in 96-well plates 
(iCycler iQ PCR plates, Bio-Rad) with a Bio-Rad iQ5 thermocycler. PCR conditions were 
95°C for 10 min, then 40 cycles of 95°C for 10 s, 55°C for 10 s, 60°C for 10 s. The ‘no 
template controls’ contained 10 µl primer mix and 10 µl PCR mix only. Positive controls 
contained the addition of 1 µl of detection device.  
Preparation of Tus-TM:TT-lock-T detection device 
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The detection device was used at a final concentration of 0.8 nM Tus-TM and 0.1 nM TT-
lock-T in the assays. TT-lock-T was first diluted to 125 nM in block buffer. Assembly of 
Tus-TM:TT-lock-T was performed by mixing 2 µl of Tus-TM (1 µM) and 2 µl of TT-lock-T 
(125 nM) together and incubating at room temperature for 10-15 min. In the ‘stepwise 
format’, the complex was diluted 1250-fold with block buffer to obtain final concentrations 
of 0.8 nM Tus-TM and 0.1 nM TT-lock-T respectively. In the ‘mixture format’, the detection 
device was diluted 50-fold with block buffer to obtain final concentrations of 20 nM Tus-TM 
and 2.5 nM TT-lock-T respectively. 
Tus-TM TT-lock qIPCR assay 
Wells were coated overnight at 4°C with 50 µl of capture antibody (anti-rabbit-HRP or anti-
human IgE at 10 µg/ml in PB). Wells were washed once and blocked with 100 µl block 
buffer for 60-90 min.  
Stepwise format: Serum or antibody samples were applied to wells and incubated for 90 min. 
Following a wash step, 50 µl of the Tus-TM:TT-lock detection device (0.8 nM Tus-TM and 
0.1 nM TT-lock-T) were added to the well and incubated for 60 min. Wells were washed 5 
times then 50 µl of 39/40 primer mix added and incubated for 60 min. A 10 µl aliquot of the 
dissociated complex was used for qPCR as for TM-HA TT-lock qIPCR assay. 
Mixture format: 2 µl of Tus-TM:TT-lock detection device (20 nM Tus-TM and 2.5 nM TT-
lock-T) were added to 50 µl of sample (as defined in the text and figure legends), mixed 
briefly then transferred to the wells for 90 min. Wells were washed 5 times then 50 µl of 
39/40 primer mix added and incubated for 60 min. qPCR was performed as described above 
using a 10 µl aliquot. 
qIPCR analysis 
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qPCR data was analysed using the iQ5 software (Bio-Rad, CA, USA) and graphed using 
GraphPad Prism (version 5.04 for Windows, GraphPad Software, CA, USA). Briefly, the 
fluorescence threshold baseline was manually adjusted to 180 fluorescence units and the 
threshold cycles (Ct) for each point extracted. Ct values were obtained by subtracting the 
experimental Ct-values from the background Ct-values generated by either the background 
control or negative serum control experiment. ∆Ct values were plotted on a semi-log graph 
and where appropriate, a non-linear regression was fit to the data using the ‘one site – 
specific binding with Hill slope’ equation. The limit of detection was set at three standard 
deviations (SD) above the mean of the background or negative serum control samples. 
 
Results 
Design and characterisation of the detection devices 
In this study we evaluated two different detection devices capable of detecting TM-specific 
antibodies that are captured on a 96-well plate. We first developed an anti-HA:Tus-HA:TT-
lock-T detection device (Figure 1C) capable of binding to a TM-HA probe. This device uses 
the bivalency of an anti-HA IgG to link a Tus-HA:TT-lock-T complex to TM-HA. Other 
systems have used streptavidin as a link between components [36-38] but the biotinylation 
process for proteins can be laborious and the extent of biotinylation often remains 
incomplete, leading to problems of reproducibility. HA-tagged recombinant proteins are easy 
to produce and are homogeneous in nature. Using a monoclonal anti-HA antibody as the 
linker therefore gives reproducible control over the stoichiometry of antibody-antigen 
complexes.  
The second detection device uses the unique combination of the Tus-TM:TT-lock-T complex 
(Figure 1D).  
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Figure 1. Schematic of TM detection devices. Maps of Tus-HA (A) and Tus-TM (B) gene 
fusions. C) Detection device for the TM-HA TT-lock qIPCR assay. The detection device 
consists of Tus-HA, a Ter-lock DNA extended with a single-stranded PCR template (TT-
lock-T) and anti-HA IgG (-HA), and is used to detect a TM-HA probe bound to TM-
specific antibodies. D) Detection device for the Tus-TM TT-lock qIPCR assay. The detection 
device consists of Tus-TM and the TT-lock-T, and is used to detect TM-specific antibodies. 
 
TM-HA and Tus-TM were purified by nickel affinity chromatography (Fig. 2A, B: lane 
NiA). The TM-HA purification was high yielding and required no further purification. Tus-
TM was poorly expressed and co-eluted with several impurities, including Tus and TM 
fragments that were the result of proteolysis (Fig. 2B: lane NiA, Tus-TM 70 kDa, Tus & TM 
fragments ~40 kDa). Gel filtration was then performed to separate Tus-TM from the 
impurities and proteolytic fragments (Fig 2B: lane GF). Some of the Tus-TM fractions still 
contained a small amount of TM (from proteolysis of Tus-TM, data not shown), but the 
presence of these contaminants should not significantly affect the assay.  
To confirm the DNA-binding activity of Tus-TM it was incubated with TerC [46] and 
visualised by EMSA. Figure 2C shows the results from an EMSA performed with Tus-TM. 
As a control Tus-HA:TerC reactions were also carried out alongside. The first lane shows 
TerC. With Tus-TM added there is a large shift in the position of the band indicating that 
Tus-TM is active in its Ter DNA-binding activity and therefore can be used in our assay.  
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Figure 2. Purity of TM-HA and Tus-TM and DNA-binding activity of Tus-HA and Tus-TM. 
A) Purification of TM-HA by nickel affinity chromatography (NiA). B) Purification of Tus-
TM by nickel affinity chromatography and gel filtration (GF). C) EMSA confirming Tus-TM 
and Tus-HA Ter-binding activity. Reactions contained 0.5 µM TerC and 2 µM Tus-TM or 
Tus-HA, 10 µl loaded.  Lane 1 contains TerC DNA alone, lanes 2 and 3 contain Tus-TM and 
Tus-HA respectively. 
 
Development of TM-HA TT-lock qIPCR assay 
As proof-of-principle the immunoassay was first performed with known quantities of TM-
sIgG obtained from rabbit. This was to simulate the capture of TM-sIgE from serum and to 
determine the limit of detection of the assay. For this assay plates were coated with anti-
rabbit-IgG in order to capture the rabbit polyclonal TM-sIgG that was applied in a 10-fold 
dilution series in block buffer. The presence of TM-sIgG was then detected by the addition of 
TM-HA and the detection device (i.e. anti-HA:Tus-HA:TT-lock-T) and quantified by qPCR 
(Figure 3A).  
First, the binding of both TM-sIgG and anti-HA IgG to TM-HA was demonstrated by 
Western Blot analysis (Figure 3B). The TM-HA TT-lock qIPCR assay was then performed 
with a 10-fold serial dilution of TM-sIgG (10 nM – 10 fM). A dose response curve was 
obtained with a detection limit of 14 pM (Figure 3C). 
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Figure 3. Development of TM-HA TT-lock qIPCR assay. A) Principle of the qIPCR assay 
for the detection of TM-sIgG. Wells were coated with anti-rabbit IgG and TM-sIgG applied 
in block buffer, followed by TM-HA then the anti-HA:Tus-HA:TT-lock-T detection device. 
B) SDS-PAGE and Western blot of TM-HA. Molecular weight marker (lane 1) and purified 
TM-HA (lane 2). TM-HA was probed with TM-sIgG (-TM, lane 3) and rat anti-HA IgG (-
HA, lane 4). C) Detection of rabbit TM-sIgG by TM-HA TT-lock qIPCR assay. TM-sIgG 
diluted in block buffer (10 fM to 10 nM) was applied to anti-rabbit IgG-coated wells and 
quantifed with the detection device and qPCR. Plot of mean and SD, N=2. 
 
As the TM-HA assay uses the bivalent properties of an antibody to bind two different 
proteins simultaneously, precise reagent concentrations have to be used to ensure optimal IgE 
detection. One downfall of this system is that it requires many incubation and wash steps, and 
reagents that could potentially cause reproducibility issues. 
Development of Tus-TM TT-lock qIPCR assay 
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The Tus-TM TT-lock qIPCR assay was designed to reduce the number of steps and reagents 
required for the detection of TM-sIgE. The assay was validated with known quantities of 
TM-sIgG both in a stepwise and mixture format (Figure 4A). A Western Blot of Tus-TM 
with anti-TM and anti-His antibodies (Figure 4B) confirmed that Tus-TM contains both Tus 
and TM domains. The Tus-TM TT-lock qIPCR assay was first validated with TM-sIgG 
diluted in block buffer and then repeated with TM-sIgG diluted in neat commercial human 
serum. This allowed us to determine if the assay was negatively affected by the serum. No 
negative effects were associated with the serum. On the contrary, we noticed a reduction in 
background Ct-values in serum conditions compared to the same assay performed in buffer 
(data not shown). It is possible that some constituents of the serum saturate the surface of the 
well and block the non-specific binding of TT-lock-T. 
Next, we tested the efficiency of the assay performed in a stepwise and in a mixture format 
(Figure 4A; see methods). This involved performing assays where the TM-sIgG was first 
applied to the wells and then the Tus-TM:TT-lock-T detection device applied in a following 
step after washing (stepwise); and comparing this to assays where the detection device was 
added directly to neat human serum (pooled commercial serum) spiked with TM-sIgG and 
applied in a single mixture to the well (Figure 4A). Results indicated (Figure 4C) that the 
mixture format performs slightly better than the stepwise format. The limit of detection for 
the mixture assay was calculated at 1.2 pM. Further experimental conditions were also tested 
(i.e. 0.4 nM Tus-TM with 50 pM or 0.4 nM TT-lock-T) in an effort to improve the limit of 
detection of the assay but all conditions tested yielded similar results (data not shown).  
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Figure 4. Development of Tus-TM TT-lock qIPCR assay. A) Schematic of Tus-TM sIgG 
detection illustrating stepwise and mixture formats. In the stepwise format, the Tus-TM:TT-
lock-T detection device is added after the TM-sIgG-spiked serum was applied to anti-rabbit 
IgG-coated plates (-rabbit-IgG). In the mixture format the detection device is added directly 
to the spiked serum. B) SDS-PAGE and Western blot of Tus-TM. Molecular weight marker 
(lane 1) and purified Tus-TM (lane 2). Tus-TM was probed with TM-sIgG (-TM, lane 3) 
and anti-His IgG (-His, lane 4). C) Comparison of stepwise (red) vs mixture (blue) formats 
for sIgG detection. Neat human serum was spiked with TM-sIgG (10 fM to 10 nM). 
Stepwise: N=2; mixture: N=2x2. D) Schematic of Tus-TM sIgE TT-lock qIPCR assay. anti-
human IgE-coated plates (-human IgE). E) Comparison of stepwise (red) vs mixture (blue) 
formats for TM-sIgE detection in serially diluted positive TM-sIgE serum (10-fold in block 
buffer). Stepwise: N=2; mixture: N=2x2. F) Comparison of stepwise and mixture formats for 
TM-sIgE detection. Positive TM-sIgE serum was diluted 1:10 in block buffer (N=6, 
CV=2.8%). Ct values were obtained by subtracting the experimental Ct-values from the 
background Ct-values generated by the negative control (negative patient serum diluted 1:10 
in block buffer). Curves were fitted by non-linear regression: one site - specific binding with 
Hill slope. 
 
To further validate and adapt our assay to the detection of TM-sIgE we coated plates with 
anti-human-IgE (Figure 4D). These experiments were performed using a commercial serum 
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that strongly tested positive for TM-sIgE by immunoblot (cf Figure 5A, lane 4). Assays were 
again performed in the stepwise and mixture formats with the positive serum serially diluted 
in block buffer (Figure 4E). The mixture format was able to detect human sIgE in positive 
serum diluted up to 230-fold (Figure 4E), demonstrating the high sensitivity of this assay. 
Notably, the stepwise format produced a higher signal compared to the mixture format. This 
was found to be due to a difference in background signal between the two formats. Indeed, 
when both formats were performed at a 1:10 serum dilution in block buffer and Ct values 
obtained for the positive serum were subtracted from those of a 1:10 dilution in block buffer 
of a negative patient serum (confirmed negative by ImmunoCAP and Immunoblot; cf Figure 
5A, lane1) then the mixture format systematically outperformed the stepwise format (mixture 
~2 ∆Ct above the stepwise format; cf Figure 4F). This confirmed our TM-sIgG data (Figure 
3C) indicating that the mixture format would be a better choice for TM-sIgE detection. 
Patient sera testing 
A small number of patients were selected to test our new Tus-TM TT-lock qIPCR assay. Our 
negative control serum was obtained from a person who is not allergic to shellfish and has 
been confirmed negative by ImmunoCAP. This sample is designated as number 1. Two 
shellfish allergic patients were used who have been also tested positive by ImmunoCAP, one 
with a low sIgE count and one with a high count. These patients are designated 2 and 3, 
respectively. The final sample is from a pooled commercial lot (Invitrogen) that was found to 
contain a high level of TM-sIgE. This was therefore used as a positive control and designated 
as sample 4.  
Serum samples were first tested for their reaction to recombinant TM by immunoblot against 
TM-HA (Figure 5A). Patients 2 and 3 (positive low and high) show a clear reaction to TM-
HA with a strong band appearing near 37 kDa. This band is missing in the negative patient 
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(1). The thick band in sample 4 demonstrates that this pooled commercial serum reacts 
strongly to our recombinant TM-HA. The immunoblots of sera 3 and 4 also have some other 
bands present that indicate a reaction to several low-abundant but antigenic E. coli proteins 
present in the sample (cf Figure 2A). The presence of small amounts of antigenic E. coli 
proteins in TM-HA are not concerning due to our assay design as they would be washed 
away during the assay and would not generate a signal even if non-specific binding were to 
occur. Furthermore, the Tus-TM purification included a gel filtration step reducing further the 
presence of these contaminants. 
Next we tested the patient sera for the presence of TM-sIgE with our Tus-TM TT-lock qIPCR 
assay. Sera were diluted 1:10 in 50 µl reactions due to limited supply. All four sera were 
tested both in stepwise and mixture formats (Figure 5B). Serum from the negative patient was 
not reactive to TM-HA and so was chosen as a negative reference sample to determine the 
background signal generated by the assay. The results confirm that the mixture format 
performs better than the stepwise format, with the signal higher in the mixture in each case. 
This is most likely due to the additional wash steps in the stepwise format resulting in more 
complex dissociation and signal reduction. There can be a trade-off between background and 
sensitivity when it comes to the number of wash steps performed in an immuno-PCR, as there 
is with ELISA. The number of washes in a TT-lock qIPCR has previously been optimised for 
different assay methods [40-42] and so formed the basis of washing protocols here. At 3 SD 
above the negative sample the positive cut-off value is 0.9 ∆Ct (mixture format). This meant 
that our positive low patient (2) would be borderline in the stepwise test and positive in the 
mixture test. As the mixture format is much more sensitive this would give us more 
opportunity to detect sIgE in allergic patients with low sIgE and to detect sensitised patients. 
All three positive patients (low ImmunoCAP positive, high ImmunoCAP positive, 
commercial positive) were significantly positive in this assay, with ∆Ct values at 3.3, 6.4 and 
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6.8 respectively. With a larger patient sample size we will be able to determine a more 
accurate cut-off point in the future. 
 
Figure 5. Detection of TM-sIgE in patient sera. Sample 1: negative, 2: positive (low 
ImmunoCAP), 3: positive (high ImmunoCAP), 4: commercial positive. A) Detection of TM-
sIgE reactivity of patient sera by immunoblot. TM-HA was transferred to PVDF membrane 
and presence of serum TM-sIgE was visualized with anti-IgE and anti-rabbit-HRP. B) 
Detection of TM-sIgE in patient sera by Tus-TM TT-lock qIPCR. Reactions were performed 
on anti-human IgE coated plates with diluted sera (10-fold in block buffer). Baseline defined 
as average of negative patient Ct values. Stepwise (red): N=2x2; mixture (blue), N=3x2. 
 
Discussion 
We have developed two different qIPCR assay platforms for the detection of TM-specific 
antibodies. Although, these assays were trialled with the major shrimp allergen TM, it is 
envisaged that they can be extended for use with other soluble allergens in the future. While 
both assays were successful in detecting TM-specific antibodies, and are of similar 
sensitivity, the Tus-TM method is simpler, faster and more robust. Furthermore, the TM-HA 
TT-lock qIPCR assay requires an additional antibody (anti-HA IgG) and fusion protein (Tus-
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HA) making the Tus-TM TT-lock qIPCR assay more cost-effective and the recommended 
choice where possible. In situations where the allergen of interest cannot be overproduced as 
a fusion with Tus then the HA assay system could be used as an alternative.  
Other than the purchase of some oligonucleotides and an anti-human IgE, the Tus-TM sIgE 
TT-lock qIPCR assay only requires the production of one recombinant Tus fusion protein and 
the use of a quantitative thermal cycler. The assay uses only 5 µl serum per reaction which is 
much less than the 40 µl required for ImmunoCAP, the most commonly used commercial 
assay. This means it could potentially be performed with a sample from a single finger prick, 
a minimally invasive procedure benefiting children especially.  
Using a reference TM-sIgG, the limit of detection was found to be approximately 1.2 pM, 
which is suitable for the detection of TM-sIgE at the lower limit cut-off for allergy. In 
diagnosis a positive patient is defined as having over 0.35 kU/l sIgE, equalling approximately 
4.7 pM (1 kU/l = 2.4 ng/ml IgE) [54]. The sensitivity of this assay is similar to the 
ImmunoCAP, which has a limit of quantitation of 1.3 pM (0.1 kU/l). A recent study 
described an aptazyme-linked oligonucelotide IgE detection assay with a limit of detection of 
1 pM [55], but this relies on the detection of total IgE as an indication of allergy. As it is 
known that the amount of total IgE is not correlated with the amount of allergen-specific IgE 
or the presence of allergy it is beneficial to develop diagnostic assays for the detection of 
allergen-specific IgE rather than total IgE. In this way it is also possible to test multiple 
allergens. With our 96-well plate assay format it would be possible to develop a screening 
system against multiple allergens at once. This would give the same benefits of allergy 
profiling that microarray offers. Correctly determining allergen sensitivity and cross-
reactivity is invaluable information to the proper management of a food allergy. ImmunoCAP 
ISAC can give allergen-specific IgE measurements for almost 50 allergen sources or semi-
quantitative measurements for 112 allergen components. Our assay provides an alternative 
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platform for profiling which would be simpler and cheaper than microarray. In a research 
laboratory situation this assay would be especially attractive.  
In summary, we have shown two new methods for TM-sIgE detection that could potentially 
be used in allergy diagnostics. The simplest of the two uses a recombinant TM tagged with 
Tus, a DNA binding protein, which can be measured by qPCR. The result is a detection 
device that will identify TM-sIgE from small amounts of serum sample. The assay was 
successful in detecting patients reactive to tropomyosin in a small sample group. Future 
studies will include a larger number of patients to further develop the diagnostic aspect of the 
immunoassay. 
Future Perspective  
The diagnosis of allergy is moving towards the identification of specific allergenic proteins 
that are relevant to each individual patient. This will lead to better control of allergies through 
customised management plans. The new qIPCR assays presented in this study will be very 
useful to achieve this goal.  We expect that our new assays will be easily amenable to the 
detection of other soluble allergens and therefore be adopted as a routine laboratory test due 
to their relative simplicity. 
Executive Summary 
Background: 
 Novel assays are needed that can identify specific IgE antibodies generated to allergenic 
proteins in sensitised patients. 
Results: 
 We have developed two quantitative immuno-PCR techniques that utilise a stable protein-
DNA conjugate (Tus-Ter-lock) to detect tropomyosin-specific antibodies.  
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 We engineered a recombinant Tus-tropomysoin fusion and performed trial assays using a 
rabbit anti-tropomyosin IgG, achieving a limit of detection of 1.2 pM. 
 Using our new Tus-TM TT-lock qIPCR assay, TM-specific IgE could be detected in 
shellfish allergic patients using only 5 µl serum per reaction. 
 The technique can be easily modified for other soluble allergens or antigens to detect 
specific antibodies in complex media. 
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